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questions as to what should be 
done with those virus stocks, and 
whether more research with live 
pox viruses should be carried out. 
The recent WHO deliberations 
were triggered by the request of 
US scientists who want to use the 
virus or some of its genes for their 
research, while others call for the 
complete destruction of the 
remaining virus samples. 
Both sides are motivated by the 
fear of smallpox being used in a 
bioterrorist attack. Experts see 
such risks as small compared with 
global health problems, but the 
widespread concerns and fears of 
such an attack, and its potential 
impact have led to detailed 
consideration by governments 
and scientists (Curr. Biol. (2004) 
14, R905). Contingency plans 
have shown that, while localized 
outbreaks could be contained 
with strategically placed 
vaccination programs, a large­
scale attack could easily lead to 
an epidemic, requiring vaccination 
programs for the entire 
population. The classic type of 
vaccine, which achieved the 
eradication of the disease, is 
highly effective but not absolutely 
safe. If all UK citizens were to 
receive this vaccine for example, 
one would have to fear around 
100 casualties. Hence the call for 
continued research into smallpox 
therapies and new vaccines, 
which would require samples of 
the virus to be kept for tests. 
Opponents of this view point to 
the risk that virus samples might 
get stolen out of one of the labs, 
or that the information obtained is 
used to reconstruct or weaponize 
the virus. As in the case of the 
2001 anthrax scare, which was 
later traced back to US 
bioweapons laboratories, the very 
research designed to provide 
protection could in fact end up as 
the source from which attackers 
might get their viral weapons. 
So is it worth keeping the virus 
to fight a small risk which one 
might multiply by this very attempt 
to banish it? The WHO seems to 
think so and has given the virus 
researchers a stay of execution, 
allowing them to continue 
research under tight supervision. 
Under the new set of rules 
prepared by a specialized 
committee and approved by the 
assembly, scientists will be able 
to carry out a limited amount of 
research with pox virus under 
WHO supervision. For example, 
they may express some of its 
genes in less dangerous host 
systems to assess their functions. 
The WHO stated that it “will 
ensure that any research will only 
be conducted after detailed 
proposals have been thoroughly 
examined on a case-by-case 
basis by the WHO Advisory 
Committee on Variola Virus 
Research, paying particular 
attention to biosafety and 
biosecurity issues.” 
At the same meeting, the 
assembly also discussed the 
progress of its ongoing plan to 
establish a strategic stockpile of 
smallpox vaccine in Geneva, 
which would be sent to any part of 
the world that needs it in an 
emergency. In addition to this 
reserve, the organization has 
asked member states to pledge 
additional stocks for international 
emergency use under WHO 
control. Currently, there are 
2.5 million doses held at Geneva, 
and an additional 31 million doses 
have been pledged by member 
countries including the United 
States and France. 
Thus, it would appear that the 
WHO is well-prepared to ensure 
that its dangerous prisoner 
remains locked up and the 
organization and its member 
states can put their resources 
towards eradicating other 
infectious diseases such as polio 
and scaling up the fight against 
those other epidemics that are 
still out there. 
Michael Gross is a science writer in 
residence at the school of 
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www.proseandpassion.com 
Stem cell sirens 
Mediawatch: Bernard Dixon 
looks at the UK reaction to two 
closely related stories. 
Was it a great triumph for the UK 
or a much more significant 
advance by a pioneering team in 
the Far East? Britain’s media were 
unsure and divided on 20 May, 
when they had to handle two 
closely related stories. The first 
was a paper in Science in which 
Woo Suk Hwang and colleagues at 
Seoul National University, South 
Korea, announced a breakthrough 
in producing stem cells from 
cloned human embryos. The 
second was the announcement of 
the first human embryo cloned in 
Britain by Miodrag Stojkovic, 
Alison Murdoch and co-workers at 
the University of Newcastle upon 
Tyne. 
The mid-market newspapers 
highlighted the UK’s achievement. 
‘Giant leap as Britain clones 
human embryo’ ran the headline 
in the Daily Express. ‘Scientists 
clone Britain’s first human 
embryo’ echoed the Daily Mail. 
Both mentioned the Korean work 
too, though the Daily Mail 
relegated this to a shorter story at 
the bottom of the page. BBC 
television and several radio 
channels gave the impression that 
the UK research was the really 
notable happening. 
The greatest contrast with UK 
triumphalism was to be found in 
The Independent, in which 
science editor Steve Connor 
authored a major news-feature 
titled ‘First stem cells taken from 
cloned embryos’, complete with 
an excellent graphic 
representation of the process 
developed in Seoul. This was 
accompanied by a much briefer 
report under a different byline on 
the Newcastle work. The 
Independent reminded readers 
that the Seoul National University 
team reported the world’s first 
cloned human embryo last year, 
and that the UK research was ‘a 
long way behind the Korean 
development’. The newspaper 
also published an editorial (‘There 
is no reason to fear this brave new 
world of hope’) that did not even 
mention the UK research. 
The Financial Times gave the 
headline ‘Asian scientists unveil 
breakthrough in stem cell cloning 
from sick patients’ to its news 
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story. This was followed by a 
feature headed ‘An Asian triumph 
for therapeutic cloning…Clive 
Cookson explains why scientists 
in Korea lead the world in human 
stem cell work that is putting 
treatment and cures for 
devastating diseases and injuries 
within reach’. 
Although the scientific data 
underlying the two stories became 
public on the same day, the 
majority of journalists may have 
taken their lead in assessing their 
relative priority from the 
Newcastle press release. It began: 
‘Newcastle University scientists 
have taken a major step forward 
in stem cell research, putting 
Britain in the vanguard of 
technology that could produce 
treatments for a range of 
conditions such as diabetes, 
Parkinson’s disease and spinal 
injuries.’ It ended: ‘The Newcastle 
team published details of their 
research simultaneously with a 
South Korean team’s 
announcement that they have 
produced 11 batches of stem 
cells containing the genes of 
patients.’ 
Under a heading ‘UK scientists 
clone human embryo’, the BBC 
News website explained this work 
before adding: ‘Meanwhile South 
Korean scientists say they have 
created stem cells to match 
individuals for the first time’. To 
their credit, both The Independent 
and The Daily Telegraph provided 
more balanced perspective. 
‘The news that a team…in 
Newcastle has created three 
human clones…was announced 
as a South Korean team disclosed 
a much more significant 
milestone’, wrote Roger Highfield 
in The Daily Telegraph. ‘The 
Koreans have succeeded in the 
efficient creation of more than 
30 cloned human embryos…They 
then dismantled the embryos to 
grow the first lines of patient­
specific embryonic cells. This 
marks the start of what many 
scientists believe will be a 
revolution in medicine.’ 
Highfield also prominently cited 
efforts by ‘biotech entrepreneur’ 
Chris Evans to set up a British 
foundation to raise hundreds of 
millions of pounds for research in 
this area. “Countries are forging 
ahead whilst we ponder our 
greatness in this field,” said 
Evans. “I still believe we can be 
the best and lead the world in this 
field if we move fast and 
decisively.” 
Local preference: One UK newspaper gives prominence to a local stem cell story over 
notable Korean advances. 
Aside from the news reporting, it 
was surprising to find virtually no 
shrill editorialising in opposition to 
the new developments, even by 
those titles that are often hostile to 
advances in biomedical science. 
Alongside The Independent’s 
robust reassurance, the papers 
that did run editorials were all 
clearly positive, though with notes 
of cool caution. ‘While the Koreans 
have moved with remarkable 
speed, we need not feel 
overwhelmed,’ said The Times. 
‘The outcome does not intensify 
the ethical issues that will always 
surround such research, but may 
even diminish them.’ 
An oft-repeated calumny 
regarding work of this sort is that 
it is raging blindly ahead, its 
practitioners ‘playing God’ or 
‘interfering with Nature’. For any 
readers tempted to buy this line, 
The Guardian provided an 
important reminder that such work 
is not out of control. ‘The 
Newcastle team operated under 
strict scrutiny,’ its editorial 
pointed out. ‘They were given a 
licence last year, under a 2001 
amendment to the Human 
Embryology Act, that was rightly 
approved by both houses of 
parliament, allowing cloning for 
therapeutic but not reproductive 
purposes.’ Feeding into that 
process had been the outcome of 
both an expert committee review 
and an extensive public 
consultation exercise. The 
Guardian also welcomed the 
‘even bigger news’ from Korea. 
‘Genetically identical matching 
stem cells…should not be 
rejected in future therapy. Let the 
research continue.’ 
The oddest aspect of media 
coverage of the two advances 
announced on 20 May — 
described by The Times Science 
Correspondent Mark Henderson 
as ‘this momentous day’ — was 
that certain tabloid newspapers 
dismissed the news in a few 
sentences or ignored it altogether. 
Could it be that some news 
editors feel that it sounds like old 
news? We’ve done that before, 
surely? 
Bernard Dixon is the European editor 
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